AstraZeneca PLC (AZN)
| Market Cap | 199.90B |
| Revenue (ttm) | 51.21B |
| Net Income (ttm) | 6.50B |
| Shares Out | 1.55B |
| EPS (ttm) | 4.15 |
| PE Ratio | 30.78 |
| Forward PE | 14.11 |
| Dividend | $1.48 (2.27%) |
| Ex-Dividend Date | Aug 9, 2024 |
| Volume | 9,010,238 |
| Open | 63.93 |
| Previous Close | 64.44 |
| Day's Range | 63.75 - 65.47 |
| 52-Week Range | 60.47 - 87.68 |
| Beta | 0.18 |
| Analysts | Buy |
| Price Target | 88.80 (+35.88%) |
| Earnings Date | Feb 6, 2025 |
About AZN
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus... [Read more]
Financial Performance
In 2023, AstraZeneca's revenue was $45.81 billion, an increase of 3.29% compared to the previous year's $44.35 billion. Earnings were $5.96 billion, an increase of 81.11%.
Financial StatementsAnalyst Forecast
According to 10 analysts, the average rating for AZN stock is "Buy." The 12-month stock price forecast is $88.8, which is an increase of 35.88% from the latest price.
News
AstraZeneca (AZN) Shares Fall After Reports of PRC Probe Alleged Fraud and Corruption – Hagens Berman
SAN FRANCISCO, Dec. 19, 2024 (GLOBE NEWSWIRE) -- AstraZeneca PLC (NASDAQ: AZN) is facing a significant crisis in China as authorities there investigate the company for alleged fraud, illegal drug impo...
AstraZeneca Digital Transformation Strategy Profile 2024 - Accelerators, Incubators and Innovation Programs
Dublin, Dec. 19, 2024 (GLOBE NEWSWIRE) -- The "Enterprise Tech Ecosystem Series: AstraZeneca Plc 2024" company profile has been added to ResearchAndMarkets.com's offering.
AstraZeneca PLC Announcement: If You Have Suffered Losses in AstraZeneca PLC (NASDAQ: AZN), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
NEW YORK, Dec. 18, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of AstraZeneca P...
AstraZeneca (AZN) Shares Fall After Reports of PRC Probe Alleged Fraud and Corruption - Hagens Berman
SAN FRANCISCO, CA / ACCESSWIRE / December 13, 2024 / AstraZeneca PLC (NASDAQ:AZN) is facing a significant crisis in China as authorities there investigate the company for alleged fraud, illegal drug i...
Tracer Biotechnologies Announces Agreement for Next-Generation Cancer Monitoring for Drug Development
NEW YORK--(BUSINESS WIRE)--Tracer Biotechnologies, a next-generation diagnostics company, today announced a multi-year project with AstraZeneca (LSE/STO/Nasdaq: AZN). The agreement will enable AstraZe...
Datopotamab Deruxtecan Demonstrated Meaningful Clinical Activity in Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung Cancer in TROPION-Lung05 and TROPION-Lung01 Pooled Analysis
TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--A pooled analysis of the TROPION-Lung05 phase 2 and the TROPION-Lung01 phase 3 trials showed datopotamab deruxtecan (Dato-DXd) demonstrated clinically mea...
IMFINZI® (durvalumab) approved in the US as first and only immunotherapy regimen for patients with limited-stage small cell lung cancer
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca's IMFINZI® (durvalumab) has been approved in the US for the treatment of adult patients with limited-stage small cell lung cancer (LS-SCLC) whose disease...
FDA approves AstraZeneca's Imfinzi for limited-stage small cell lung cancer
The U.S. Food and Drug Administration has approved AstraZeneca blockbuster drug Imfinzi to treat some adults with limited-stage small cell lung cancer, the health regulator said on Wednesday.
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of AstraZeneca PLC (AZN) on Behalf of Investors
LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of AstraZeneca PLC (...
AstraZeneca names new international Executive VP to succeed Leon Wang
AstraZeneca said on Wednesday Iskra Reic will become its new international executive vice president succeeding Leon Wang, who was detained by Chinese authorities in October.
The Law Offices of Frank R. Cruz Announces Investigation of AstraZeneca PLC (AZN) on Behalf of Investors
LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of AstraZeneca PLC (“AstraZeneca” or the “Company”) (NASDAQ: AZN) on behalf of investors concerning the Compan...
AstraZeneca's Enhertu included in China's state insurance reimbursement
AstraZeneca's blockbuster breast cancer drug will be added to China's national reimbursement scheme list, according to an update from the National Healthcare Security Administration.
AstraZeneca asthma drug more effective during attack than steroids, study finds
AstraZeneca's Fasenra, an injectable treatment for severe asthma, is more effective during attacks than the oral steroid that has been the standard of care for 50 years, cutting the need for further t...
AstraZeneca awards $3.5M for projects to improve access to healthcare for patients across the US
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca today pledged $3.5 million to nonprofit organizations across the US as part of Accelerate Change Together (ACT) on Health Equity, an initiative to improv...
RFK Jr.'s HHS nomination sparks concern over pharma stocks
President-elect Trump's decision to nominate Robert F. Kennedy Jr. as the Secretary of Health and Human Services (HHS) has sparked concerns, particularly about his skepticism toward the pharmaceutical...
GRAIL Announces First Patient Tested With Blood-Based Assay in Global Phase 3 Adjuvant Lung Cancer Study
MENLO PARK, Calif. , Nov. 18, 2024 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that the first patien...
Lunit Announces Collaboration with AstraZeneca to Develop AI-Powered Digital Pathology Risk Assessment Tools for NSCLC
Collaboration to harness Lunit SCOPE Genotype Predictor for rapid and convenient prediction of non-small cell lung cancer driver mutations SEOUL, South Korea , Nov. 18, 2024 /PRNewswire/ -- Lunit (KRX...
Vaccine Maker Stocks Slump After RFK Jr. Nominated as HHS Head
In the 2024 presidential election's latest impact on the stock markets, shares of several vaccine makers were down Friday morning following the nomination of Robert F. Kennedy Jr. to head the Departme...
Pharma shares hit as Trump picks RFK Jr to lead health department
Choice of vaccine critic knocks some of world's biggest drugmakers including Moderna, AstraZeneca and GSK
Bullish Opportunities in AZN
Tony Zhang with @OptionsPlay says AstraZeneca (AZN) has more going for it than its stock chart may show. Following the company's latest earnings, he points to strength in key metrics as a sign for bul...
AstraZeneca: Strong Growth Potential And Market Volatility Offer Opportunity
AstraZeneca PLC aims for $80 billion revenue by 2030, driven by strong growth in oncology, biopharmaceuticals, and rare diseases, despite recent share price declines. The company's weight management p...
Healthy Returns: AstraZeneca expands U.S. investment plan on confidence in economy
AstraZeneca said it is doubling down on its investment in its U.S. business. Meanwhile, General Catalyst has agreed to purchase Summa Health for $485 million.